CO6660505A2 - Compuestos heterocíclicos, su preparación y su aplicación terapéutica - Google Patents
Compuestos heterocíclicos, su preparación y su aplicación terapéuticaInfo
- Publication number
- CO6660505A2 CO6660505A2 CO12231930A CO12231930A CO6660505A2 CO 6660505 A2 CO6660505 A2 CO 6660505A2 CO 12231930 A CO12231930 A CO 12231930A CO 12231930 A CO12231930 A CO 12231930A CO 6660505 A2 CO6660505 A2 CO 6660505A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- methods
- preparation
- heterocyclic compounds
- therapeutic application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Esta invención está dirigida a compuestos de la formula I o un pro fármaco del mismo, útiles como inhibidores de quinasa selectivos, a los métodos para producir dichos compuestos y a los métodos para tratar, prevenir o mejorar un trastorno mediado por quinasa En particular, los métodos se refieren a tratar o mejorar un trastorno que implica la desregulación de tirosina quinasa incluyendo enfermedades cardiovasculares, diabetes, trastornos asociados con la diabetes, enfermedades inflamatorias, trastornos inmunológicos, cáncer y enfermedades del ojo tales como retinopatías, degeneración macular u otras enfermedades vitreoretinianas, y semejantes, en donde la formula I es:
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305665 | 2010-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6660505A2 true CO6660505A2 (es) | 2013-04-30 |
Family
ID=43033247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12231930A CO6660505A2 (es) | 2010-06-22 | 2012-12-21 | Compuestos heterocíclicos, su preparación y su aplicación terapéutica |
Country Status (27)
Country | Link |
---|---|
US (1) | US20130123271A1 (es) |
EP (1) | EP2585439A1 (es) |
JP (1) | JP2013533237A (es) |
KR (1) | KR20130116070A (es) |
CN (1) | CN103140480A (es) |
AR (1) | AR081960A1 (es) |
AU (1) | AU2011268938A1 (es) |
BR (1) | BR112012032721A2 (es) |
CA (1) | CA2803496A1 (es) |
CL (1) | CL2012003637A1 (es) |
CO (1) | CO6660505A2 (es) |
CR (1) | CR20120653A (es) |
DO (1) | DOP2012000317A (es) |
EA (1) | EA201291329A1 (es) |
EC (1) | ECSP12012354A (es) |
GT (1) | GT201200345A (es) |
IL (1) | IL223721A0 (es) |
MA (1) | MA34384B1 (es) |
MX (1) | MX2012015305A (es) |
NI (1) | NI201200193A (es) |
NZ (1) | NZ605022A (es) |
PE (1) | PE20130640A1 (es) |
SG (1) | SG186424A1 (es) |
TN (1) | TN2012000610A1 (es) |
TW (1) | TW201204723A (es) |
UY (1) | UY33461A (es) |
WO (1) | WO2011161159A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
CA2914521A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
SG11201509351UA (en) * | 2013-06-10 | 2015-12-30 | Bayer Pharma AG | Novel compounds for the treatment of cancer |
SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
KR101960624B1 (ko) | 2014-12-24 | 2019-03-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 이소퀴놀린 화합물 |
TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
JP7029806B2 (ja) * | 2016-04-08 | 2022-03-04 | ベイラー カレッジ オブ メディスン | ステロイド受容体コアクチベーターの小分子レギュレーター及びその使用方法 |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
CN115916759A (zh) * | 2020-06-19 | 2023-04-04 | 南京红云生物科技有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6056684B2 (ja) | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4407792A (en) | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
US20050084835A1 (en) | 2003-10-16 | 2005-04-21 | The Singing Machine Company, Inc. | Karaoke system with built-in camera |
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
JP5275628B2 (ja) | 2004-08-25 | 2013-08-28 | ターゲジェン インコーポレーティッド | 複素環式化合物および使用方法 |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2006101977A2 (en) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
WO2006118256A1 (ja) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
MX2007008848A (es) | 2005-06-08 | 2008-04-16 | Targegen Inc | Metodos y composiciones para el tratamiento de desordenes oculares. |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
WO2008020203A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
EA200900819A1 (ru) | 2006-12-22 | 2010-02-26 | Новартис Аг | Хиназолины для ингибирования pdk1 |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US20100311965A1 (en) | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
JP2012514020A (ja) | 2008-12-29 | 2012-06-21 | フォーヴィア・ファーマシューティカルズ | 置換キナゾリン化合物 |
CN102317288A (zh) * | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
-
2011
- 2011-06-21 AR ARP110102137A patent/AR081960A1/es unknown
- 2011-06-21 TW TW100121689A patent/TW201204723A/zh unknown
- 2011-06-22 CN CN2011800407027A patent/CN103140480A/zh active Pending
- 2011-06-22 JP JP2013515883A patent/JP2013533237A/ja not_active Withdrawn
- 2011-06-22 KR KR1020137001581A patent/KR20130116070A/ko not_active Application Discontinuation
- 2011-06-22 MX MX2012015305A patent/MX2012015305A/es not_active Application Discontinuation
- 2011-06-22 MA MA35572A patent/MA34384B1/fr unknown
- 2011-06-22 PE PE2012002466A patent/PE20130640A1/es not_active Application Discontinuation
- 2011-06-22 EP EP11729591.5A patent/EP2585439A1/en not_active Withdrawn
- 2011-06-22 SG SG2012094173A patent/SG186424A1/en unknown
- 2011-06-22 BR BR112012032721A patent/BR112012032721A2/pt not_active IP Right Cessation
- 2011-06-22 CA CA2803496A patent/CA2803496A1/en not_active Abandoned
- 2011-06-22 WO PCT/EP2011/060445 patent/WO2011161159A1/en active Application Filing
- 2011-06-22 UY UY0001033461A patent/UY33461A/es unknown
- 2011-06-22 EA EA201291329A patent/EA201291329A1/ru unknown
- 2011-06-22 NZ NZ605022A patent/NZ605022A/en not_active IP Right Cessation
- 2011-06-22 AU AU2011268938A patent/AU2011268938A1/en not_active Abandoned
- 2011-06-22 US US13/805,479 patent/US20130123271A1/en not_active Abandoned
-
2012
- 2012-12-18 IL IL223721A patent/IL223721A0/en unknown
- 2012-12-19 CR CR20120653A patent/CR20120653A/es unknown
- 2012-12-19 TN TNP2012000610A patent/TN2012000610A1/en unknown
- 2012-12-19 DO DO2012000317A patent/DOP2012000317A/es unknown
- 2012-12-20 GT GT201200345A patent/GT201200345A/es unknown
- 2012-12-20 NI NI201200193A patent/NI201200193A/es unknown
- 2012-12-21 CO CO12231930A patent/CO6660505A2/es not_active Application Discontinuation
- 2012-12-21 CL CL2012003637A patent/CL2012003637A1/es unknown
- 2012-12-21 EC ECSP12012354 patent/ECSP12012354A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201204723A (en) | 2012-02-01 |
CA2803496A1 (en) | 2011-12-29 |
EA201291329A1 (ru) | 2013-05-30 |
TN2012000610A1 (en) | 2014-04-01 |
JP2013533237A (ja) | 2013-08-22 |
CL2012003637A1 (es) | 2013-07-05 |
WO2011161159A1 (en) | 2011-12-29 |
SG186424A1 (en) | 2013-01-30 |
EP2585439A1 (en) | 2013-05-01 |
CR20120653A (es) | 2013-04-03 |
NI201200193A (es) | 2013-05-13 |
UY33461A (es) | 2012-01-31 |
MA34384B1 (fr) | 2013-07-03 |
PE20130640A1 (es) | 2013-03-30 |
NZ605022A (en) | 2013-12-20 |
MX2012015305A (es) | 2013-05-30 |
CN103140480A (zh) | 2013-06-05 |
DOP2012000317A (es) | 2013-04-15 |
US20130123271A1 (en) | 2013-05-16 |
AU2011268938A1 (en) | 2013-01-24 |
ECSP12012354A (es) | 2013-01-31 |
BR112012032721A2 (pt) | 2016-11-29 |
KR20130116070A (ko) | 2013-10-22 |
IL223721A0 (en) | 2013-03-05 |
GT201200345A (es) | 2014-01-24 |
AR081960A1 (es) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6660505A2 (es) | Compuestos heterocíclicos, su preparación y su aplicación terapéutica | |
PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
ECSP11011250A (es) | [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
MX2015005831A (es) | Antagonistas de il-6 y usos de los mismos. | |
CO6751270A2 (es) | Compuestos y composiciones como inhibidores de la trk | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
ECSP11011204A (es) | Compuestos de quinazolina sustituidos | |
IN2015DN00542A (es) | ||
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
WO2012125408A8 (en) | Pegylated apelin and uses thereof | |
CR20150248A (es) | Derivados de oxazolidin-2-ona-pirimidina | |
DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
ECSP15025868A (es) | Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso | |
AR122753A2 (es) | Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas | |
CL2011002626A1 (es) | Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |